# Inhaled liposomal ciprofloxacin protects against lethal tularemia in the common marmoset

**Authors:** Rachel E. Ireland, Alejandro Nunez, Wendy Butcher, Carwyn Davies, James D. Blanchard, Francis Dayton, Igor Gonda, Sarah V. Harding, Michelle Nelson

PMC · DOI: 10.1128/aac.01232-25 · Antimicrobial Agents and Chemotherapy · 2025-12-19

## TL;DR

Inhaled liposomal ciprofloxacin protects marmosets from lethal tularemia, a bacterial disease, and is effective when treatment starts at fever onset.

## Contribution

This study demonstrates the efficacy of inhaled liposomal ciprofloxacin in a nonhuman primate model of tularemia.

## Key findings

- All animals treated with ciprofloxacin, either inhaled or oral, survived the study, while all untreated animals died.
- Inhaled ciprofloxacin led to bacterial clearance in nearly all treated animals.
- Treatment reduced physiological and immunological responses compared to untreated animals.

## Abstract

Francisella tularensis is a gram-negative, intracellular bacterium that causes the disease tularemia. Tularemia is prevalent in North America, Europe, and Asia and is typically treated with injected and orally administered antibiotics, including streptomycin, gentamicin, doxycycline, and ciprofloxacin, administered for 10 to 21 days. New therapeutic options are required to reduce the potential of a relapse of disease. Inhaled liposomal-encapsulated ciprofloxacin has demonstrated protection in a murine model of tularemia. The efficacy was further assessed in a nonhuman primate model of tularemia. Mixed-sex common marmosets were challenged with F. tularensis by the inhalational route, and the efficacy of ciprofloxacin delivered by either the inhalational (Apulmiq liposomal formulation) or oral route was compared. Antibiotics were initiated either at 24 h post-challenge (post-exposure prophylaxis) or at the onset of fever (treatment) and continued for 7 days. All control (untreated) animals succumbed to infection by 8 days post-challenge. All animals that received antibiotics, by either route, survived the duration of the study, with bacterial clearance in all but one animal that received inhalational ciprofloxacin. Antibiotic treatment also reduced the physiological and immunological responses observed when compared to animals that received no antibiotics. Histological changes in the lungs were less frequent, although mild, resolving lesions were present in animals treated with ciprofloxacin delivered at the onset of fever by either route.

## Linked entities

- **Chemicals:** ciprofloxacin (PubChem CID 2764), streptomycin (PubChem CID 5297), gentamicin (PubChem CID 3467), doxycycline (PubChem CID 54671203)
- **Diseases:** tularemia (MONDO:0018077)
- **Species:** Francisella tularensis (taxon 263)

## Full-text entities

- **Diseases:** Tularemia (MESH:D014406), infection (MESH:D007239), fever (MESH:D005334)
- **Chemicals:** doxycycline (MESH:D004318), Apulmiq (-), ciprofloxacin (MESH:D002939), gentamicin (MESH:D005839), streptomycin (MESH:D013307)
- **Species:** Mus musculus (house mouse, species) [taxon 10090], Callithrix jacchus (common marmoset, species) [taxon 9483], Francisella tularensis (species) [taxon 263]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12888874/full.md

## Figures

9 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12888874/full.md

## References

42 references — full list in the complete paper: https://tomesphere.com/paper/PMC12888874/full.md

---
Source: https://tomesphere.com/paper/PMC12888874